<DOC>
	<DOCNO>NCT02004275</DOCNO>
	<brief_summary>This randomized phase I/II trial study side effect best dose pomalidomide ixazomib give together dexamethasone see well pomalidomide dexamethasone without ixazomib work treat patient refractory multiple myeloma . Biological therapy , pomalidomide dexamethasone , may stimulate immune system different way stop tumor cell grow . Ixazomib may stop growth tumor cell block enzymes need cell growth . It yet know whether pomalidomide dexamethasone effective without ixazomib treat multiple myeloma .</brief_summary>
	<brief_title>Pomalidomide Dexamethasone With Without Ixazomib Treating Patients With Refractory Multiple Myeloma</brief_title>
	<detailed_description>This phase I , dose-escalation study pomalidomide , dexamethasone ixazomib follow phase II study . The primary purpose Phase I portion study establish maximum tolerate dose combination therapy pomalidomide/dexamethasone/ixazomib . Patients receive pomalidomide orally ( PO ) daily ( QD ) day 1-21 , dexamethasone PO QD day 1 , 8 , 15 , 22 , ixazomib PO QD day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression , unacceptable toxicity withdrawal consent . About 24 patient take part portion study . The primary purpose Phase II portion study ass whether combination pomalidomide/dexamethasone/ixazomib improve progression free survival relative pomalidomide/dexamethasone . Please see `` Arms '' section detail description treatment arm Phase II study . The dose pomalidomide ixazomib determine phase I study . About 108 patient take part portion study . The secondary objective list . Secondary Phase I Objectives : 1 . To determine dose-limiting toxicity ( DLTs ) 2 . To analyze type grade serious adverse event ( SAEs ) 3 . To analyze type grade adverse event ( AEs ) 4 . To analyze reason incidence dose modifications/omissions/delays 5 . To assess preliminary evidence clinical efficacy Secondary Phase II Objectives : 1 . To evaluate overall response rate ( ORR ) , partial response ( PR ) , good partial response ( VGPR ) , complete response ( CR ) stringent CR ( sCR ) rate pomalidomide/dexamethasone/ixazomib compare pomalidomide/dexamethasone 2 . To assess clinical benefit rate ( CBR : minimal response ( MR ) + ORR ) pomalidomide/dexamethasone/ixazomib compare pomalidomide/dexamethasone 3 . To assess disease control rate ( DCR : stable disease ( SD ) + CBR ) pomalidomide/dexamethasone/ixazomib compare pomalidomide/dexamethasone 4 . For patient achieve PR well , ass whether combination pomalidomide/dexamethasone/ixazomib increase duration response ( DOR ) compare pomalidomide/dexamethasone . 5 . To assess whether combination pomalidomide/dexamethasone/ixazomib improve overall survival ( OS ) compare take pomalidomide/dexamethasone alone . 6 . To assess time next treatment ( TNT ) patient take pomalidomide/dexamethasone/ixazomib compare pomalidomide/dexamethasone . 7 . To evaluate safety pomalidomide/dexamethasone/ixazomib compare pomalidomide/dexamethasone . 8 . For patient pomalidomide/dexamethasone arm opt cross-over pomalidomide/dexamethasone/ixazomib arm , assessment response rate ( ORR , CBR , DCR ) DOR , TNT , PFS , OS evaluate date cross-over . 9 . To determine baseline level perceive fatigue overall quality life ( QOL ) associate OS . Patients follow every 4 week disease progression , death withdrawal inform consent .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Eligibility Criteria : 1 . Documentation Disease : Histologically confirm diagnosis symptomatic multiple myeloma . 2 . Measurable disease : 1 . Serum Mprotein ≥ 1.0 g/dL and/or 2 . Urine Mprotein ≥ 200 mg/24 hour and/or 3 . Involved serum free light chain level ≥ 10 mg/dL abnormal serum free light chain ratio and/or 4 . Baseline marrow burden myeloma least 30 % 3 . Prior Treatment : 1 . Previously treat symptomatic multiple myeloma 2 . Lenalidomide proteasome inhibitorrefractory multiple myeloma ( dual refractory disease ) Lenalidomide proteasome inhibitorrefractory disease define disease progression progression within 60 day last dose lenalidomide proteasome inhibitorbased treatment . Patients receive least 2 cycle lenalidomide proteasome inhibitorbased regimen standard dos evaluable refractoriness . Patients refractory either bortezomib carfilzomib need refractory . Patients refractory lenalidomide proteasome inhibitor give sequentially part different line therapy therapy include combination lenalidomide proteasome inhibitor . 3 . At least 2 prior line systemic therapy multiple myeloma A line therapy myeloma define 1 planned cycle single agent combination therapy , well planned series treatment regimen administer sequential manner ( e.g . lenalidomide , bortezomib dexamethasone induction therapy 4 cycle follow autologous stem cell transplantation lenalidomide maintenance therapy would consider 1 line prior therapy ) . A new line therapy begin plan therapy modify include treatment agent ( alone combination ) result disease progression , disease relapse treatmentrelated toxicity ( e.g . patient progress face lenalidomide maintenance therapy bortezomib dexamethasone add regimen ) . A new line therapy also begin planned treatmentfree interval interrupt need start treatment due disease relapse/progression ( e.g . patient relapse myeloma achieves partial response plan 8 cycle cyclophosphamide , bortezomib dexamethasone , enjoy 8month period therapy experience disease progression require reinitiation therapy ) . 4 . Allogeneic stem cell transplantation allow provided patient ≥ 1 year transplant , immunosuppressive therapy treat/prevent graftversushost disease , evidence active graft versus host disease , evidence active infection meet criteria participation . 5 . No chemotherapy radiation therapy within 14 day prior registration 6 . No investigational agent within 21 day prior registration 7 . Pomalidomide naïve pomalidomide sensitive disease allow phase I phase II Sensitivity pomalidomide define MR well prior pomalidomidebased therapy maintain ≥60 day last dose therapy . 8 . No concurrent investigational therapy 9 . No major surgery within 28 day prior registration 10 . Patients receive GCSF ( Filgrastim ) GMCSF ( Sargramostim ) within 1 week screen Pegfilgrastim within 2 week screen meet eligibility criterion 4 . Nonpregnant nonnursing : A female childbearing potential sexually mature female undergone hysterectomy bilateral oophorectomy naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . 1 . Women childbearing potential must negative serum urine pregnancy test sensitivity least 25 mlU/ml 14 day prior therapy repeat within 24 hour start pomalidomide 2 . Women childbearing potential must either commit complete abstinence heterosexual contact begin two acceptable method birth control , one highly effective method one additional effective ( barrier ) method , time , start pomalidomide 3 . Females childbearing potential must agree ongoing pregnancy test . 4 . Men must practice complete abstinence agree use condom sexual contact female childbearing potential even successful vasectomy . 5 . All participant must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 6 . Participating woman pregnant nursing 5 . ≥18 year age 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 7 . Required Initial Laboratory Values : 1 . Absolute Neutrophil Count ( ANC ) ≥ 1.0 x 10^9/L 2 . Platelet Count ≥ 50 x 10^9/L 3 . Calculated Creatinine Clearance* ≥ 50 mL/min 4 . Total Bilirubin &lt; 1.5 x upper limit normal ( ULN ) 5 . AST ALT &lt; 2.5 x upper limit normal ( ULN ) Calculated utilizing CockcroftGault formula 24hour urine collection 8 . Intercurrent Recent Illness : 1 . No central nervous system involvement 2 . No primary refractory multiple myeloma primary refractory multiple myeloma define disease nonresponsive patient never achieve minimal response ( MR ) good therapy course disease primary refractory multiple myeloma also include patient never achieve minimal response ( MR ) well significant change Mprotein evidence clinical progression well patient meet criterion true progressive disease ( PD ) 3 . No primary secondary plasma cell leukemia 4 . No amyloid lightchain ( AL ) amyloidosis polyneuropathy , organomegaly , endocrinopathy , monoclonal , gammopathy skin change ( POEMS ) syndrome 5 . No known active hepatitis C base +HCV antibody ( confirm ) , +HCV ribonucleic acid ( RNA ) liver disease history positive serology 6 . No known hepatitis B surface antigen positivity 7 . No previous hypersensitivity component study treatment 8 . No prior history erythema multiforme thalidomide lenalidomide treatment 9 . Peripheral Neuropathy ≤ Grade 2 10 . Adequate cardiac function define : 1 . No electrocardiography ( EKG ) evidence acute ischemia 2 . No EKG evidence active , clinically significant conduction system abnormalities 3 . No EKG evidence &gt; Grade 2 ( &gt; 480 m ) quantum tunnel composite ( QTc ) prolongation 4 . Prior study entry , EKG abnormality screen felt put patient risk document investigator medically significant 5 . No uncontrolled angina severe ventricular arrhythmia 6 . No clinically significant pericardial disease 7 . No history myocardial infarction within last 6 month 8 . No Class 3 high New York Heart Association Congestive Heart Failure 11 . Concomitant Treatment Patients strong inducer cytochrome P450 ( CYP ) 3A4 CYP1A2 strong inhibitor CYP3A4 CYP1A2 . Ixazomib substrate CYP3A4 CYP1A2 . For additional information potential drugdrug drugfood interaction ixazomib , please see protocol . Strong CYP3A4 inducer prohibit ( example ) : phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. John 's Wort Strong CYP3A4 inhibitor prohibit : boceprevir indinavir nelfinavir lopinavir saquinavir telaprevir ritonavir clarithromycin conivaptan itraconazole ketoconazole mibefradil nefazodone posaconazole voriconazole telithromycin Strong CYP1A2 inhibitor prohibit : fluvoxamine ciprofloxacin 12 . Human Immunodeficiency virus ( HIV ) infection Patients HIV infection eligible , provide meet follow : 1 . No history Acquired Immune Deficiency Syndrome ( AIDS ) define condition HIV relate illness 2 . CD4+ cell nadirs &gt; 350/mm^3 3 . Treatment sensitive HIV , antiHIV therapy , HIV viral load &lt; 50 copies/mm^3 Please note : HIV+ patient enroll study assign treatment ixazomib may need modify antiretroviral therapy prior receive protocol therapy strong inducer potent inhibitor cytochrome P450 3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>